Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-grown stem cells may restore damaged eye surfaces

NCT ID NCT00845117

Disease control Sponsor: Veerle Van Gerwen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a graft made from a patient's own or donor stem cells can repair the cornea's surface in people with limbal stem cell deficiency, a condition that causes pain, scarring, and vision loss. A small biopsy of limbal tissue is taken from a healthy eye or donor, stem cells are grown into a sheet in the lab, and then transplanted onto the damaged eye. The trial measures improvements in vision, surface healing, and blood vessel growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cultivated limbal stem cell graft
What this could lead to
If successful, this approach could restore a clear corneal surface and improve vision in people with limbal stem cell deficiency, potentially reducing the need for corneal transplants.
What could go wrong
This is a small, early-stage study with 21 participants, so results may not apply to everyone. Risks include graft failure, infection, or rejection, and long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Start date

Jul 2008

Finished

Jun 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients suffering from LSCD IIa and IIb. Those suffering from IIc may be included once inflammation has subsided and cornea can be staged as IIb. * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. * Women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: * Subjects who are pregnant or lactating * Subjects who have sensitivity to drugs that provide local anesthesia * Subjects suffering from active infection of the external eye * Medical conditions that prohibit the use of systemic immunosuppression (in cases of allogenic transplantation)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Limbal stem cell deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aniridia limbal stem cell deficiency pterygium Stevens-Johnson syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Limbal stem cell deficiency

Contacts and locations

Locations

  • University Hospital Antwerp

    Antwerp, Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.